AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1651434
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Combination treatment)
Trial: 11720639
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Unfractionated heparin)
Trial: 26541888
Drug: Encapsulated ileal-release
RxNorm normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated ileal-release glutamine (6.0 g)
Trial: 23661494
Drug: 8-week preoperative
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week preoperative neuromuscular supervised exercise programme delivered twice a week for 1 hour as adjunct treatment to standard arthroplasty procedure
Trial: 21110409
Drug: High-dosage (HD)
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage (HD) medical exercise therapy
Trial: 21110409
Drug: Low-dosage (LD)
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage (LD) exercise therapy
Trial: 17956016
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 200 g twice-daily (b.i.d.)
Trial: 17956016
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 200 g once-daily (q.d.)
Trial: 17956016
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg three times daily (t.i.d.)
Trial: 15875135
Drug: N2O administration
RxNorm normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N2O administration during washout of sevoflurane
Trial: 12584874
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (NTP; n = 27)
Trial: 12584874
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR plus nicotine patch (B + NTP; n = 61)
Trial: 7978436
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg triazolam orally (Group 1)
Trial: 7978436
Drug: 75 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 micrograms oral clonidine (Group 2)
Trial: 7978436
Drug: 150 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms oral clonidine (Group 3)
Trial: 7978436
Drug: 300 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms oral clonidine (Group 4)
Trial: 4407085
Drug: Intravenous dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextran 70
Trial: 4407085
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Subcutaneous heparin and Intravenous dextran 70)
Trial: 31449685
Drug: No concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No concomitant antiplatelet therapy (Control group)
Trial: 28534153
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms (Bevacizumab monotherapy and Bevacizumab plus carboplatin)
Trial: 23416308
Drug: GS-9620 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9620 (0.3, 1, 2, 4, 6, 8 or 12 mg)
Trial: 23416308
Drug: GS-9620 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9620 (8 or 12 mg)
Trial: 23416308
Drug: GS-9620 (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9620 (≥ 2 mg)
Trial: 21135022
Drug: ABT‐874 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐874 200 mg every other week (EOW)
Trial: 21135022
Drug: ABT‐874 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐874 200 mg every week (EW)
Trial: 3461725
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg + codeine 16 mg + caffeine 30 mg
Trial: 31886591
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention (two consultations with a pharmacist 1-2 and 3-5 weeks after filling the prescription)
Trial: 29437940
Drug: Standard LTBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard LTBI treatment plus two-way weekly text messaging
Trial: 29437940
Drug: Standard LTBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard LTBI treatment
Trial: 21912072
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg/day for 6 months)
Trial: 17449579
Drug: Vitamins (folate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins (folate 1 mg, vitamin B‐12 500 microg, vitamin B‐6 10 mg)
Trial: 8083788
Drug: Saline group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group, irrigation with 2 cc of physiologic saline
Trial: 8083788
Drug: Tetracycline group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline group, irrigation with 2 cc of aqueous tetracycline hydrochloride, 50 mg/ml (5%)
Trial: 8083788
Drug: Chlorhexidine group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine group, irrigation with 2 cc 0.12% chlorhexidine
Trial: 2686071
Drug: Nifedipine (NF)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NF) administered regularly for 2 months
Trial: 2686071
Drug: Nifedipine (NF)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NF) withdrawal after 2 months of administration
Trial: 31430755
Drug: CBT (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT (Cognitive Behaviour Therapy)
Trial: 29197203
Drug: Pharmacotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy and exercise
Trial: 16938144
Drug: Extended cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended cognitive behaviour therapy (CBT) with or without behaviour strategies
Trial: 15340532
Drug: Sequential antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential antiviral group (thymosin alpha1 1.6 mg, subcutaneous injection, 2 times/week for 8 weeks; interferon 500 MU, muscle injection, every other day for 6 months; lamivudine 100 mg/day after HBeAg seroconversion or interferon withdrawal for more than 18 months)
Trial: 15340532
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (interferon and thymosin alpha1 simultaneously for 6 months)
Trial: 15340532
Drug: Lamivudine group
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine group (more than 18 months treatment with lamivudine)
Trial: 9598254
Drug: 0.3 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg.kg‐1 mivacurium
Trial: 7834990
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion at 10 ng min‐1 kg‐1
Trial: 7834990
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion at 2 ng min‐1 kg‐1
Trial: 7834990
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion at 5 ng min‐1 kg‐1
Trial: 7834990
Drug: D‐aldosterone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐aldosterone infusion
Trial: 3165298
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b (IFN alpha-2b) administered three times a week at doses of 2 or 5 X 10(6) IU/m2 for chronic phase patients; 5 X 10(6) IU/m2 for accelerated phase patients.
Trial: 3165298
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of Interferon alpha-2b (IFN alpha-2b) at doses from 2 to 5 X 10(6) IU/m2.
Trial: 3165298
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b (IFN alpha-2b) treatment.
Trial: 23485864
Drug: Saline/GHRP-2 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/GHRP-2 infusion
Trial: 10839492
Drug: Neoadjuvant chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy, concomitant chemotherapy, or radiotherapy alone
Trial: 9324434
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of D5W
Trial: 24615132
Drug: Mass azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mass azithromycin treatment (once-treated communities)
Trial: 24615132
Drug: Mass azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mass azithromycin treatment (twice-treated communities)
Trial: 21186648
Drug: Alternating magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternating magnetic field treatment
Trial: 16641573
Drug: HAMS-ORS (50g/L)
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAMS-ORS (50g/L)
Trial: 16641573
Drug: G-ORS (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-ORS (control)
Trial: 8627205
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aerosol (25, 50, or 100 mg bid for 12 weeks)
Trial: 3898416
Drug: Combined steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined steroid and beta-stimulant preparation (salbutamol 100 micrograms/puff and beclomethasone dipropionate 50 micrograms/puff)
Trial: 30098982
Drug: Prior local
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior local treatment
Trial: 20535923
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose BVC (0.5 mg/kg)
Trial: 20535923
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose BVC (1.0 mg/kg)
Trial: 15705234
Drug: 15 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/d wolfberry (estimated to contain almost 3 mg zeaxanthin) for 28 days
Trial: 10534967
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) oxycodone (administered every 12 hours)
Trial: 10534967
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) oxycodone (4 times a day)
Trial: 1675763
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (400 mg per kilogram of body weight) every 28 days
Trial: 22383996
Drug: Cocoa+hazelnuts+phytosterols (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa+hazelnuts+phytosterols (2 g/d)
Trial: 22383996
Drug: Cocoa+hazelnuts+phytosterols+soluble fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa+hazelnuts+phytosterols+soluble fiber (20 g/d)
Trial: 22383996
Drug: Cocoa cream
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa cream (control)
Trial: 19384121
Drug: Concurrent vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent vaginal dinoprostone (3 mg pessary) and oxytocin infusion
Trial: 19384121
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion only (placebo)
Trial: 17463140
Drug: LCT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCT treatment group
Trial: 9576405
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy for 6 months with targeted INR of 2.0 to 2.85
Trial: 9576405
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy for 6 months
Trial: 9576405
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy for 6 months or indefinitely
Trial: 9576405
Drug: No anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulation therapy during the follow-up period
Trial: 7713766
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with 3 cycles of carboplatin/5-fluorouracil prior to surgery and radiotherapy (arm A)
Trial: 10550374
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with surgery and radiotherapy (arm B)
Trial: 2105793
Drug: Pituitary suppression
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pituitary suppression with buserelin followed by pure follicle stimulating hormone
Trial: 346430
Drug: Cimetidine (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.6 g per day)
Trial: 23663795
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training with a load of 40% of maximal inspiratory pressure, 5 sets of 10 breaths, twice a day, 7 days a week.
Trial: 8087515
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy and radiotherapy (vindesine, cyclophosphamide, cisplatin, and lomustine) with a radiation dose of 65 Gy
Trial: 8087515
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone with a radiation dose of 65 Gy
Trial: 2790539
Drug: Thymostimulin (TP‐1)
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (TP‐1) at 1 mg/kg for 14 days then weekly for 12 weeks
Trial: 4633061
Drug: Twice-weekly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly oral regimen of isoniazid plus PAS
Trial: 4633061
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral regimen of isoniazid plus PAS
Trial: 29172212
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 80 mg per day until the day of surgery (group 1)
Trial: 29172212
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) stopped 4 days before surgery (group 2)
Trial: 23001939
Drug: Catechin-rich oil
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catechin-rich oil palm leaf extract (OPLE) 0.5 g day(‐1)
Trial: 17294997
Drug: Intramuscular 1
RxNorm normalized name: Zyprexa IntraMuscular 10mg Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 1 mg/kg tramadol
Trial: 17294997
Drug: Intramuscular 1
RxNorm normalized name: Zyprexa IntraMuscular 10mg Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 1 mg/kg meperidine
Trial: 17294997
Drug: Intramuscular 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 0.5 mg/kg ketamine
Trial: 10377734
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with interferon-alpha-2b (3 MU, three times a week) and ribavirin (1000-1200 mg daily) for one year
Trial: 10377734
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with interferon-alpha-2b and ribavirin
Trial: 8927233
Drug: Amantadine (AMA)
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine (AMA) 100 mg, tid
Trial: 8927233
Drug: Biperiden (BIP)
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biperiden (BIP) 2 mg, tid
Trial: 1712193
Drug: Moricizine 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine 750 mg/day
Trial: 1712193
Drug: Disopyramide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide 600 mg/day
Trial: 7112396
Drug: Preoperative intralymphatic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative intralymphatic immunotherapy with MER-BCG, surgical excision with regional lymphadenectomy, and postoperative monthly intradermal vaccinations with BCG
Trial: 30522922
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.8 mg/kg) + cyclophosphamide (750 mg/m2) + doxorubicin (50 mg/m2) + prednisone (100 mg) (A+CHP)
Trial: 30522922
Drug: Cyclophosphamide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (750 mg/m2) + doxorubicin (50 mg/m2) + vincristine (1.4 mg/m2) + prednisone (100 mg) (CHOP)
Trial: 25106776
Drug: Topical Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Steroid (S)
Trial: 16117818
Drug: r‐HuEPO (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO (50 U/kg, administered three times a week for 25 days)
Trial: 12191566
Drug: 25mg TNFR:Fc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg TNFR:Fc administered twice a week for 10 weeks
Trial: 10192108
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (enteric coated capsule containing 90 mg peppermint oil and 50 mg caraway oil)
Trial: 10192108
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (enteric soluble formulation containing 36 mg peppermint oil and 20 mg caraway oil)
Trial: 10192108
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation
Trial: 7766746
Drug: Ispaghula, 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ispaghula, 3.5 g twice a day
Trial: 7766746
Drug: Vancomycin, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin, 250 mg t.d.s. per os
Trial: 1361068
Drug: Salmeterol 100
RxNorm normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 100 micrograms twice daily
Trial: 29870855
Drug: PCT-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-guided therapy (n=275)
Trial: 22541305
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) as an adjunct to eccentric exercises
Trial: 22541305
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment as an adjunct to eccentric exercises
Trial: 19074534
Drug: MDMA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (100 mg) with ethanol (0.6 per thousand)
Trial: 19074534
Drug: MDMA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (100 mg) alone
Trial: 7859051
Drug: Bendroflumethiazide 2.5-5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 2.5-5.0 mg
Trial: 12526280
Drug: Enalapril 10-20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10-20 mg
Trial: 8453855
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg twice a day)
Trial: 2698934
Drug: Nifedipine +
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine + Chlorthalidone (both at the same doses)
Trial: 779554
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 0.1 mg per kg
Trial: 30768766
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily subcutaneous semaglutide
Trial: 30768766
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily 3.0 mg liraglutide
Trial: 17290039
Drug: Fluticasone 500
RxNorm normalized name: FLUTICASONE 500MCG/SALMETEROL 50MCG INHL,ORAL,DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 500 microg, twice a day